Erratum: Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality (European Journal of Endocrinology (2017) 176:4 (471-480) DOI: 10.1530/EJE-16-0969);Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality

European Journal of Endocrinology

Volumn 176, Issue 4, 2017, Pages 471-480

  Bancos, Irina ^a,b   Hazeldine, Jon ^c,d   Chortis, Vasileios ^a,e   Hampson, Peter ^c,d   Taylor, Angela E ^a,e   Lord, Janet M ^c,d   Arlt, Wiebke ^a,e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MAYO CLINIC   (United States)

^c Institute of Inflammation and Ageing   (United States)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e Birmingham Women s Hospital NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; REACTIVE OXYGEN METABOLITE;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CELL DENSITY; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTRACELLULAR SPACE; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; MORTALITY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUTROPHIL; PHAGOCYTOSIS; PRIMARY ADRENAL INSUFFICIENCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; YOUNG ADULT; ADDISON DISEASE; ADOLESCENT; IMMUNOLOGY; METABOLISM;

ADDISON DISEASE; ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES; YOUNG ADULT;

EID: 85014972078     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-16-0969e     Document Type: Erratum

References (33)

1. The Nobel Prize in Physiology or Medicine 1950. Nobelprize.org. Nobel Media AB 2014. Web. 28 Mar 2016.
2. Bancos I, Hahner S, Tomlinson J & Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes & Endocrinology 2015 3 216-226. (doi:10.1016/S2213-8587(14)70142-1)
3. Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, Ventz M, Quinkler M & Allolio B. Epidemiology of adrenal crisis in chronic adrenal insufficiency: The need for new prevention strategies. European Journal of Endocrinology 2010 162 597-602. (doi:10.1530/EJE-09-0884)
4. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W & Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. Journal of Clinical Endocrinology & Metabolism 2007 92 3912-3922. (doi:10.1210/jc.2007-0685)
5. Lovas K, Loge JH & Husebye ES. Subjective health status in Norwegian patients with Addison"s disease. Clinical Endocrinology 2002 56 581-588. (doi:10.1046/j.1365-2265.2002.01466.x)
6. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A & Johannsson G. Premature mortality in patients with Addison"s disease: A populationbased study. Journal of Clinical Endocrinology & Metabolism 2006 91 4849-4853. (doi:10.1210/jc.2006-0076)
7. Erichsen MM, Lovas K, Fougner KJ, Svartberg J, Hauge ER, Bollerslev J, Berg JP, Mella B & Husebye ES. Normal overall mortality rate in Addison"s disease, but young patients are at risk of premature death. European Journal of Endocrinology 2009 160 233-237. (doi:10.1530/EJE-08-0550)
8. Burman P, Mattsson AF, Johannsson G, Hoybye C, Holmer H, Dahlqvist P, Berinder K, Engstrom BE, Ekman B, Erfurth EM et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology & Metabolism 2013 98 1466-1475. (doi:10.1210/jc.2012-4059)
9. Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K, Milovanovic D, Beuschlein F, Willenberg HS, Quinkler M & Allolio B. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: A prospective study. Journal of Clinical Endocrinology & Metabolism 2015 100 407-416. (doi:10.1210/jc.2014-3191)
10. Smans LC, Souverein PC, Leufkens HG, Hoepelman AI & Zelissen PM. Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: A cohort study. European Journal of Endocrinology 2013 168 609-614. (doi:10.1530/EJE-12-0879)
11. O'Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, Stewart PM, Tomlinson JW & Arlt W. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: The utility of serum androstenedione. Journal of Clinical Endocrinology & Metabolism 2014 99 1027-1036.
12. Chadwick CA, Owen LJ & Keevil BG. Development of a method for the measurement of dehydroepiandrosterone sulphate by liquidchromatography-tandem mass spectrometry. Annals of Clinical Biochemistry 2005 42 468-474. (doi:10.1258/000456305774538175)
13. Godoy-Ramirez K, Franck K & Gaines H. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. Journal of Immunological Methods 2000 239 35-44. (doi:10.1016/S0022-1759(00)00161-7)
14. Edvardsen K, Bjanesoy T, Hellesen A, Breivik L, Bakke M, Husebye ES & Bratland E. Peripheral blood cells from patients with autoimmune Addison"s disease poorly respond to interferons in vitro, despite elevated serum levels of interferon-inducible chemokines. Journal of Interferon & Cytokine Research 2015 35 759-770. (doi:10.1089/jir.2014.0171)
15. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A & Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs 2014 74 1195-1207. (doi:10.1007/s40265-014-0259-8)
16. Hazeldine J, Arlt W & Lord JM. Dehydroepiandrosterone as a regulator of immune cell function. Journal of Steroid Biochemistry and Molecular Biology 2010 120 127-136. (doi:10.1016/j.jsbmb.2009.12.016)
17. Coles AJ, Thompson S, Cox AL, Curran S, Gurnell EM & Chatterjee VK. Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. European Journal of Immunology 2005 35 3694-3703. (doi:10.1002/eji.200526128)
18. Mavoungou E, Bouyou-Akotet MK & Kremsner PG. Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30). Clinical & Experimental Immunology 2005 139 287-296. (doi:10.1111/j.1365-2249.2004.02686.x)
19. Gatti G, Cavallo R, Sartori ML, del Ponte D, Masera R, Salvadori A, Carignola R & Angeli A. Inhibition by cortisol of human natural killer (NK) cell activity. Journal of Steroid Biochemistry and Molecular Biology 1987 26 49-58. (doi:10.1016/0022-4731(87)90030-6)
20. Duggal NA, Upton J, Phillips AC, Hampson P & Lord JM. NK cell immunesenescence is increased by psychological but not physical stress in older adults associated with raised cortisol and reduced perforin expression. Age 2015 37 9748. (doi:10.1007/s11357-015-9748-2)
21. Logan RW, Wynne O, Levitt D, Price D & Sarkar DK. Altered circadian expression of cytokines and cytolytic factors in splenic natural killer cells of Per1(-/-) mutant mice. Journal of Interferon & Cytokine Research 2013 33 108-114. (doi:10.1089/jir.2012.0092)
22. Cuesta M, Cermakian N & Boivin DB. Glucocorticoids entrain molecular clock components in human peripheral cells. FASEB Journal 2015 29 1360-1370. (doi:10.1096/fj.14-265686)
23. Lanier LL. NK cell recognition. Annual Review of Immunology 2005 23 225-274. (doi:10.1146/annurev.immunol.23.021704.115526)
24. MacFarlane AWt & Campbell KS. Signal transduction in natural killer cells. Current Topics in Microbiology and Immunology 2006 298 23-57. (doi:10.1007/3-540-27743-9-2)
25. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007 109 4816-4824. (doi:10.1182/blood-2006-07-035519)
26. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW & Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001 409 1055-1060. (doi:10.1038/35059110)
27. Garg A, Barnes PF, Porgador A, Roy S, Wu S, Nanda JS, Griffith DE, Girard WM, Rawal N, Shetty S et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. Journal of Immunology 2006 177 6192-6198. (doi:10.4049/jimmunol.177.9.6192)
28. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Arico M, Moretta L & Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005 106 566-571. (doi:10.1182/blood-2004-10-4035)
29. Bjanesoy TE, Andreassen BK, Bratland E, Reiner A, Islam S, Husebye ES & Bakke M. Altered DNA methylation profile in Norwegian patients with autoimmune Addison's disease. Molecular Immunology 2014 59 208-216. (doi:10.1016/j.molimm.2014.02.018)
30. Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S & Lee DA. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Molecular Immunology 2013 54 296-301. (doi:10.1016/j.molimm.2012.12.012)
31. Triolo TM, Baschal EE, Armstrong TK, Toews CS, Fain PR, Rewers MJ, Yu L, Miao D, Eisenbarth GS, Gottlieb PA et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. Journal of Clinical Endocrinology & Metabolism 2009 94 4517-4523. (doi:10.1210/jc.2009-1308)
32. Whitaker MJ, Debono M, Huatan H, Merke DP, Arlt W & Ross RJ. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clinical Endocrinology 2014 80 554-561. (doi:10.1111/cen.12316)
33. Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley LA, Digweed D, Eckland DJ, Van Ryzin C, Nieman LK, Arlt W et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2015 100 1137-1145. (doi:10.1210/jc.2014-3809)